R. Pharmaceuticals, . Diagnostics, . Ge-healthcare, E. Avid, . Lilly et al., He is co-inventor in patents relating to biological markers and/or diagnostics and has not received any royalties

P. Johannsen, E. Salmon, and H. Hampel, Assessing Therapeutic Efficacy in a Progressive Disease, CNS Drugs, vol.56, issue.4, pp.311-325, 2006.
DOI : 10.2165/00023210-200620040-00005

P. Crane and R. Doody, DONEPEZIL TREATMENT OF PATIENTS WITH MCI: A 48-WEEK RANDOMIZED, PLACEBO- CONTROLLED TRIAL, Neurology, vol.73, issue.18, pp.1514-1515, 2009.
DOI : 10.1212/WNL.0b013e3181bd6c25

R. Doody, S. Ferris, and S. Salloway, Donepezil treatment of patients with MCI: A 48-week randomized, placebo-controlled trial, Neurology, vol.72, issue.18, 2009.
DOI : 10.1212/01.wnl.0000344650.95823.03

R. Doody, S. Ferris, and S. Salloway, Safety and Tolerability of Donepezil in Mild Cognitive Impairment: Open-Label Extension Study, American Journal of Alzheimer's Disease & Other Dementias??, vol.57, issue.3, pp.155-159, 2010.
DOI : 10.1177/1533317509352334

H. Feldman, S. Gauthier, and J. Hecker, A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease, Neurology, vol.57, issue.4, 2001.
DOI : 10.1212/WNL.57.4.613

H. Feldman, S. Gauthier, and J. Hecker, Efficacy of Donepezil on Maintenance of Activities of Daily Living in Patients with Moderate to Severe Alzheimer's Disease and the Effect on Caregiver Burden, Journal of the American Geriatrics Society, vol.10, issue.Suppl. 2, 2003.
DOI : 10.1046/j.1365-2389.2003.51260.x

H. Feldman, S. Gauthier, and J. Hecker, Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial, International Journal of Geriatric Psychiatry, vol.277, issue.6, 2005.
DOI : 10.1002/gps.1325

S. Gauthier, H. Feldman, and J. Hecker, Efficacy of Donepezil on Behavioral Symptoms in Patients With Moderate to Severe Alzheimers Disease, International Psychogeriatrics, vol.14, issue.4, pp.389-404, 2002.
DOI : 10.1017/S104161020200858X

R. Petersen, R. Thomas, and M. Grundman, Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment, New England Journal of Medicine, vol.352, issue.23, 2005.
DOI : 10.1056/NEJMoa050151

S. Salloway, S. Ferris, and A. Kluger, Efficacy of donepezil in mild cognitive impairment: A randomized placebo-controlled trial, Neurology, vol.63, issue.4, 2004.
DOI : 10.1212/01.WNL.0000134664.80320.92

S. Teipel, A. Drzezga, P. Bartenstein, H. Möller, M. Schwaiger et al., Effects of donepezil on cortical metabolic response to activation during 18FDG-PET in Alzheimer???s disease: a double-blind cross-over trial, Psychopharmacology, vol.11, issue.1, pp.86-94, 2006.
DOI : 10.1007/s00213-006-0408-1

C. Jack, J. Petersen, R. Grundman, and M. , Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI, Neurobiology of Aging, vol.29, issue.9, 2008.
DOI : 10.1016/j.neurobiolaging.2007.03.004

N. Schuff, J. Suhy, and R. Goldman, An MRI substudy of a donepezil clinical trial in mild cognitive impairment, Neurobiology of Aging, vol.32, issue.12, pp.2318-2331, 2011.
DOI : 10.1016/j.neurobiolaging.2010.04.005

B. Dubois, M. Chupin, and H. Hampel, Donepezil decreases annual rate of 16 Core candidate neurochemical and imaging biomarkers of Alzheimer's disease

S. Teipel, T. Meindl, L. Grinberg, H. Heinsen, and H. Hampel, Novel MRI techniques in the assessment of dementia, European Journal of Nuclear Medicine and Molecular Imaging, vol.275, issue.7, 2008.
DOI : 10.1007/s00259-007-0703-z

M. Wagner, S. Wolf, and F. Reischies, Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease, Neurology, vol.78, issue.6, 2012.
DOI : 10.1212/WNL.0b013e318245f447

M. Sarazin, V. Chauviré, and E. Gerardin, The amnestic syndrome of hippocampal type in Alzheimer's disease: an MRI study, J Alzheimers Dis, vol.22, issue.1, pp.285-294, 2010.

W. Rosen, R. Mohs, and K. Davis, A new rating scale for Alzheimer's disease

M. Reitan and D. , The Halstead-Reitan Neuropsychological Test Battery: Theory and clinical interpretation, 1993.

A. Benton, The revised visual retention test: The Psychological Corporation, 1974.

J. Bernal-rusiel, D. Greve, M. Reuter, B. Fischl, M. Sabuncu et al., Statistical analysis of longitudinal neuroimage data with Linear Mixed Effects models, NeuroImage, vol.66, pp.249-260, 2013.
DOI : 10.1016/j.neuroimage.2012.10.065

M. Reuter, H. Rosas, B. Fischl, M. Reuter, N. Schmansky et al., Highly accurate inverse consistent registration: 26 Within-subject template estimation for unbiased longitudinal image analysis, Neuroimage, 2012.

R. Desikan, F. Ségonne, and B. Fischl, An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest, NeuroImage, vol.31, issue.3, pp.968-980, 2006.
DOI : 10.1016/j.neuroimage.2006.01.021

G. F. Templeton, J. Morris, and B. Dickerson, A Two-Step Approach for Transforming Continuous Variables to Normal: Implications and Recommendations for IS Research The cortical signature of prodromal AD: regional thinning predicts mild AD dementia, Communications of the AIS Neurology, vol.2872, issue.12, pp.1048-1055, 2009.

B. Dickerson, D. Wolk, and I. Asdn, MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults, Neurology, vol.78, issue.2, 2012.
DOI : 10.1212/WNL.0b013e31823efc6c

K. Krishnan, H. Charles, and P. Doraiswamy, Randomized, placebocontrolled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease, Am J Psychiatry, 2003.

N. Schuff, N. Woerner, and L. Boreta, MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers, Brain, vol.132, issue.4, pp.1067-1077, 2009.
DOI : 10.1093/brain/awp007

B. Dubois, M. Chupin, and H. Hampel, Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease, Alzheimer's & Dementia, vol.11, issue.9, 2015.
DOI : 10.1016/j.jalz.2014.10.003

T. Arendt, V. Bigl, A. Tennstedt, and A. Arendt, Neuronal loss in different parts of the nucleus basalis is related to neuritic plaque formation in cortical target areas in alzheimer's disease, Neuroscience, vol.14, issue.1, pp.1-14, 1985.
DOI : 10.1016/0306-4522(85)90160-5

S. Kar, S. Slowikowski, D. Westaway, and H. Mount, Interactions between betaamyloid and central cholinergic neurons: implications for Alzheimer's disease

N. Selden, D. Gitelman, N. Salamon-murayama, T. Parrish, and M. Mesulam, Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain, Brain, vol.121, issue.12, pp.2249-2257, 1998.
DOI : 10.1093/brain/121.12.2249